Novel biomarkers in chronic heart failure

[1]  J. Lupón,et al.  Combined use of high‐sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure , 2012, European journal of heart failure.

[2]  I. Piña,et al.  Galectin-3 in Ambulatory Patients With Heart Failure: Results From the HF-ACTION Study , 2012, Circulation. Heart failure.

[3]  X. Rabasseda,et al.  A report from the American Heart Association Scientific Sessions 2011 (November 12-16, 2011, Orlando, Florida, USA). , 2012, Drugs of today.

[4]  J. Januzzi,et al.  Emerging biomarkers in heart failure. , 2012, Clinical chemistry.

[5]  V. Harjola,et al.  Cystatin C: a step forward in assessing kidney function and cardiovascular risk , 2012, Heart Failure Reviews.

[6]  Karen A. Hartman,et al.  Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure , 2011, Heart.

[7]  Yingying Tang,et al.  A Dual Mechanism for IKs Current Reduction by the Pathogenic Mutation KCNQ1‐S277L , 2011, Pacing and clinical electrophysiology : PACE.

[8]  M. Ackerman,et al.  The diagnostic utility of recovery phase QTc during treadmill exercise stress testing in the evaluation of long QT syndrome. , 2011, Heart rhythm.

[9]  L. Tavazzi,et al.  Clinical outcome of renal tubular damage in chronic heart failure. , 2011, European heart journal.

[10]  G. Felker.  Biomarkers as surrogate end points in heart failure trials. , 2011, Heart failure clinics.

[11]  D. Sawyer,et al.  Neuregulin-1β for the treatment of systolic heart failure. , 2011, Journal of molecular and cellular cardiology.

[12]  Junjie Xiao,et al.  The genetics of atrial fibrillation: from the bench to the bedside. , 2011, Annual review of genomics and human genetics.

[13]  P. Muntendam,et al.  Galectin-3 in heart failure: high levels are associated with all-cause mortality. , 2011, International journal of cardiology.

[14]  Andrea Mazzanti,et al.  Long-term follow-up of patients with short QT syndrome. , 2011, Journal of the American College of Cardiology.

[15]  James D. Thomas,et al.  Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. , 2011, The American journal of cardiology.

[16]  H. Calkins,et al.  HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). , 2011, Heart rhythm.

[17]  P. Schwartz,et al.  Transient outward current (I(to)) gain-of-function mutations in the KCND3-encoded Kv4.3 potassium channel and Brugada syndrome. , 2011, Heart rhythm.

[18]  G. Jakl,et al.  Complementary role of copeptin and high‐sensitivity troponin in predicting outcome in patients with stable chronic heart failure , 2011, European journal of heart failure.

[19]  D. Giannessi.  Multimarker approach for heart failure management: perspectives and limitations. , 2011, Pharmacological research.

[20]  E. Ashley,et al.  Systems biology of heart failure, challenges and hopes , 2011, Current opinion in cardiology.

[21]  G. Lip,et al.  Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. , 2011, Journal of the American College of Cardiology.

[22]  J. Rehfeld,et al.  Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure. , 2011, JAMA.

[23]  G. Navis,et al.  Current and novel renal biomarkers in heart failure , 2011, Heart Failure Reviews.

[24]  S. Butz,et al.  GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice , 2011, Nature Medicine.

[25]  Eric Boerwinkle,et al.  Cardiac Troponin T Measured by a Highly Sensitive Assay Predicts Coronary Heart Disease, Heart Failure, and Mortality in the Atherosclerosis Risk in Communities Study , 2011, Circulation.

[26]  L. Påhlman,et al.  Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer , 2011, British Journal of Cancer.

[27]  A. Ishani,et al.  Renal Biomarkers of Kidney Injury in Cardiorenal Syndrome , 2011, Current heart failure reports.

[28]  D. Tester,et al.  Genetic Testing for Potentially Lethal, Highly Treatable Inherited Cardiomyopathies/Channelopathies in Clinical Practice , 2011, Circulation.

[29]  P. Kowey,et al.  A novel mutation in the KCNH2 gene associated with short QT syndrome. , 2011, Journal of molecular and cellular cardiology.

[30]  A. Wu,et al.  High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure , 2011, Circulation. Heart failure.

[31]  G. Schuler,et al.  Growth-differentiation factor 15 as predictor of mortality in acute reperfused ST-elevation myocardial infarction: insights from cardiovascular magnetic resonance , 2011, Heart.

[32]  M. Gollob,et al.  The short QT syndrome: proposed diagnostic criteria. , 2011, Journal of the American College of Cardiology.

[33]  P. Ponikowski,et al.  Identification of Chronic Heart Failure Patients with a High 12-Month Mortality Risk Using Biomarkers Including Plasma C-Terminal Pro-Endothelin-1 , 2011, PloS one.

[34]  P. Macdonald,et al.  Parenteral administration of recombinant human neuregulin‐1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses , 2011, European journal of heart failure.

[35]  Hans L Hillege,et al.  Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction , 2010, Annals of medicine.

[36]  Annukka M. Lahtinen,et al.  KCNE1 D85N polymorphism — a sex-specific modifier in type 1 long QT syndrome? , 2011, BMC Medical Genetics.

[37]  C. Frampton,et al.  Biomarker-guided treatment of heart failure: still waiting for a definitive answer. , 2010, Journal of the American College of Cardiology.

[38]  M. Prins,et al.  Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. , 2010, Journal of the American College of Cardiology.

[39]  M. Ackerman,et al.  Implantable cardioverter defibrillator therapy for congenital long QT syndrome: a single-center experience. , 2010, Heart rhythm.

[40]  J. Rehfeld,et al.  Prognostic assessment of elderly patients with symptoms of heart failure by combining high-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide measurements. , 2010, Clinical chemistry.

[41]  R. Giugliano,et al.  Novel biomarkers in cardiovascular disease: update 2010. , 2010, American heart journal.

[42]  P. Schwartz,et al.  Gain-of-function mutation S422L in the KCNJ8-encoded cardiac K(ATP) channel Kir6.1 as a pathogenic substrate for J-wave syndromes. , 2010, Heart rhythm.

[43]  Christopher M O'Connor,et al.  Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. , 2010, Journal of the American College of Cardiology.

[44]  M. Christ-Crain,et al.  The stress hormone copeptin: a new prognostic biomarker in acute illness. , 2010, Swiss medical weekly.

[45]  A. Moss,et al.  Beta‐Blocker Efficacy in High‐Risk Patients with the Congenital Long‐QT Syndrome Types 1 and 2: Implications for Patient Management , 2010, Journal of cardiovascular electrophysiology.

[46]  C. Antzelevitch,et al.  Short QT Syndrome: From Bench to Bedside , 2010, Circulation. Arrhythmia and electrophysiology.

[47]  M. Picard,et al.  Galectin‐3, cardiac structure and function, and long‐term mortality in patients with acutely decompensated heart failure , 2010, European journal of heart failure.

[48]  R. Bellazzi,et al.  Polymorphisms in the NOS1AP gene modulate QT interval duration and risk of arrhythmias in the long QT syndrome. , 2010, Journal of the American College of Cardiology.

[49]  J. Timmermans,et al.  The rate-dependent biophysical properties of the LQT1 H258R mutant are counteracted by a dominant negative effect on channel trafficking. , 2010, Journal of molecular and cellular cardiology.

[50]  Ruben Coronel,et al.  The Brugada ECG Pattern: A Marker of Channelopathy, Structural Heart Disease, or Neither? Toward a Unifying Mechanism of the Brugada Syndrome , 2010, Circulation. Arrhythmia and electrophysiology.

[51]  Liuquan Cheng,et al.  A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. , 2010, Journal of the American College of Cardiology.

[52]  P. Ponikowski,et al.  Mid‐regional pro‐adrenomedullin as a novel predictor of mortality in patients with chronic heart failure , 2010, European journal of heart failure.

[53]  S. Réhman,et al.  Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. , 2010, American heart journal.

[54]  Charles Antzelevitch,et al.  J wave syndromes. , 2010, Heart rhythm.

[55]  L. Tavazzi,et al.  The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI‐heart failure (GISSI‐HF) trial , 2010, European journal of heart failure.

[56]  O. Pongs,et al.  Ancillary subunits associated with voltage-dependent K+ channels. , 2010, Physiological reviews.

[57]  A. Skanes,et al.  Utility of Treadmill Testing in Identification and Genotype Prediction in Long-QT Syndrome , 2010, Circulation. Arrhythmia and electrophysiology.

[58]  L. Allen,et al.  Use of Multiple Biomarkers in Heart Failure , 2010, Current cardiology reports.

[59]  M. Buemi,et al.  From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confines of nephrology , 2010, European journal of clinical investigation.

[60]  Nancy R. Cook,et al.  Assessing the Incremental Role of Novel and Emerging Risk Factors , 2010, Current cardiovascular risk reports.

[61]  M. Zhou,et al.  Neuregulin Signaling and Heart Failure , 2010, Current heart failure reports.

[62]  M Borggrefe,et al.  Long-Term Prognosis of Patients Diagnosed With Brugada Syndrome: Results From the FINGER Brugada Syndrome Registry , 2010, Circulation.

[63]  H. Hillege,et al.  Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study , 2010, Clinical Research in Cardiology.

[64]  A. Siegbahn,et al.  Growth-Differentiation Factor-15 for Long-Term Risk Prediction in Patients Stabilized After an Episode of Non–ST-Segment–Elevation Acute Coronary Syndrome , 2010, Circulation. Cardiovascular genetics.

[65]  H. Piper,et al.  Growth differentiation factor 15 acts anti‐apoptotic and pro‐hypertrophic in adult cardiomyocytes , 2009, Journal of cellular physiology.

[66]  J. Cohn,et al.  Relation to Disease Severity and Prognosis in the Valsartan Heart Failure Trial , 2010 .

[67]  M. Horie,et al.  Prognostic role of highly sensitive cardiac troponin I in patients with systolic heart failure. , 2010, American heart journal.

[68]  J. Struck,et al.  Prognostic value of emerging neurohormones in chronic heart failure during optimization of heart failure-specific therapy. , 2010, Clinical chemistry.

[69]  A. Bayés‐Genís,et al.  Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure. , 2010, Revista espanola de cardiologia.

[70]  C. O'connor,et al.  Biomarker guided therapy for heart failure: focus on natriuretic peptides , 2010, Heart Failure Reviews.

[71]  C. Frampton,et al.  N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. , 2009, Journal of the American College of Cardiology.

[72]  Heike Wulff,et al.  Voltage-gated potassium channels as therapeutic targets , 2009, Nature Reviews Drug Discovery.

[73]  Juan Cinca,et al.  Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. , 2009, Journal of the American College of Cardiology.

[74]  Michael J Ackerman,et al.  Genotype-phenotype aspects of type 2 long QT syndrome. , 2009, Journal of the American College of Cardiology.

[75]  Yi-Lwun Ho,et al.  The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. , 2009, Clinica chimica acta; international journal of clinical chemistry.

[76]  T. Mueller,et al.  Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma--the Presage ST2 assay. , 2009, Clinica chimica acta; international journal of clinical chemistry.

[77]  Michael J Ackerman,et al.  Genetic Testing for Long-QT Syndrome: Distinguishing Pathogenic Mutations From Benign Variants , 2009, Circulation.

[78]  Fabio Mosca,et al.  Prevalence of the Congenital Long-QT Syndrome , 2009, Circulation.

[79]  Richard T. Lee,et al.  Interleukin-33 Prevents Apoptosis and Improves Survival After Experimental Myocardial Infarction Through ST2 Signaling , 2009, Circulation. Heart failure.

[80]  Ramon Brugada,et al.  Genetics of familial atrial fibrillation. , 2009, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[81]  Michael Christiansen,et al.  The genetic basis of Brugada syndrome: A mutation update , 2009, Human mutation.

[82]  M. Horie,et al.  A novel KCNH2 mutation as a modifier for short QT interval. , 2009, International journal of cardiology.

[83]  J. Killian,et al.  Prognostic Value of Biomarkers in Heart Failure: Application of Novel Methods in the Community , 2009, Circulation. Heart failure.

[84]  M. Frenneaux,et al.  Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy , 2009, European heart journal.

[85]  A. Moss,et al.  Mutations in Conserved Amino Acids in the KCNQ1 Channel and Risk of Cardiac Events in Type‐1 Long‐QT Syndrome , 2009, Journal of cardiovascular electrophysiology.

[86]  Kevin Bersell,et al.  Neuregulin1/ErbB4 Signaling Induces Cardiomyocyte Proliferation and Repair of Heart Injury , 2009, Cell.

[87]  Nancy R Cook,et al.  Advances in Measuring the Effect of Individual Predictors of Cardiovascular Risk: The Role of Reclassification Measures , 2009, Annals of Internal Medicine.

[88]  P. Schwartz.  Cutting nerves and saving lives. , 2009, Heart rhythm.

[89]  M. Ackerman,et al.  Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery. , 2009, Heart rhythm.

[90]  R. Schnabel,et al.  Growth-Differentiation Factor-15 for Risk Stratification in Patients With Stable and Unstable Coronary Heart Disease: Results From the AtheroGene Study , 2009, Circulation. Cardiovascular genetics.

[91]  F. Harrell,et al.  Criteria for Evaluation of Novel Markers of Cardiovascular Risk: A Scientific Statement From the American Heart Association , 2009, Circulation.

[92]  K. Dickstein,et al.  C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. , 2009, European heart journal.

[93]  S. Viskin,et al.  The QT interval: too long, too short or just right. , 2009, Heart rhythm.

[94]  K. Dickstein,et al.  Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. , 2009, European heart journal.

[95]  J. Pu,et al.  Aminoglycoside antibiotics restore functional expression of truncated HERG channels produced by nonsense mutations. , 2009, Heart rhythm.

[96]  T. Lindahl,et al.  Cystatin C and NT‐proBNP, a powerful combination of biomarkers for predicting cardiovascular mortality in elderly patients with heart failure: results from a 10‐year study in primary care , 2009, European journal of heart failure.

[97]  E. W. Hancock,et al.  AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American , 2009, Journal of the American College of Cardiology.

[98]  A. Wilde,et al.  Empiric quinidine therapy for asymptomatic Brugada syndrome: time for a prospective registry. , 2009, Heart rhythm.

[99]  S. Viskin,et al.  Excellent Long‐Term Reproducibility of the Electrophysiologic Efficacy of Quinidine in Patients with Idiopathic Ventricular Fibrillation and Brugada Syndrome , 2009, Pacing and clinical electrophysiology : PACE.

[100]  E. W. Hancock,et al.  AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the , 2009, Circulation.

[101]  Rinaldo Bellomo,et al.  Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery—A prospective cohort study* , 2009, Critical care medicine.

[102]  O. Carretero,et al.  N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. , 2009, American journal of physiology. Heart and circulatory physiology.

[103]  A. Wilde,et al.  Ventricular Fibrillation with Prominent Early Repolarization Associated with a Rare Variant of KCNJ8/KATP Channel , 2009, Journal of cardiovascular electrophysiology.

[104]  G. Novo,et al.  Biomarkers in heart failure. , 2009, Frontiers in bioscience.

[105]  E. Antman,et al.  Evaluation of high-sensitivity assays for cardiac troponin. , 2009, Clinical chemistry.

[106]  L. Irwig,et al.  Assessing new biomarkers and predictive models for use in clinical practice: a clinician's guide. , 2008, Archives of internal medicine.

[107]  R. Fitzgerald,et al.  Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. , 2008, Journal of cardiac failure.

[108]  R. Bruner,et al.  The M&A , 2008 .

[109]  S. Viskin,et al.  J-point elevation in survivors of primary ventricular fibrillation and matched control subjects: incidence and clinical significance. , 2008, Journal of the American College of Cardiology.

[110]  Elisabetta Cerbai,et al.  Role of potassium currents in cardiac arrhythmias. , 2008, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[111]  Tsuyoshi Ono,et al.  Nifekalant and Disopyramide in a Patient with Short QT Syndrome: Evaluation of Pharmacological Effects and Electrophysiological Properties , 2008, Pacing and clinical electrophysiology : PACE.

[112]  Hiroshi Morita,et al.  The QT syndromes: long and short , 2008, The Lancet.

[113]  Jørgen K. Kanters,et al.  Functional Effects of KCNE3 Mutation and Its Role in the Development of Brugada Syndrome , 2008, Circulation. Arrhythmia and electrophysiology.

[114]  J. Struck,et al.  Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. , 2008, Journal of the American College of Cardiology.

[115]  J. Hoheisel,et al.  Coronary disease; , 2004 .

[116]  Arthur A M Wilde,et al.  Accurate electrocardiographic assessment of the QT interval: teach the tangent. , 2008, Heart rhythm.

[117]  Matteo E Mangoni,et al.  Genesis and regulation of the heart automaticity. , 2008, Physiological reviews.

[118]  F. van Lente,et al.  Impact of myocardial function on cystatin C measurements in chronic systolic heart failure. , 2008, Journal of cardiac failure.

[119]  Thomas Lavergne,et al.  Sudden cardiac arrest associated with early repolarization. , 2008, The New England journal of medicine.

[120]  Francesco Prati,et al.  From bench to bedside: a novel technique of acquiring OCT images. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[121]  Charles Antzelevitch,et al.  Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome. , 2008, Heart rhythm.

[122]  C. Antzelevitch,et al.  Pharmacological approach to the treatment of long and short QT syndromes. , 2008, Pharmacology & therapeutics.

[123]  S. Priori,et al.  The Brugada syndrome. , 2008, Journal of the American College of Cardiology.

[124]  O. Carretero,et al.  Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. , 2008, American journal of physiology. Heart and circulatory physiology.

[125]  K. Lemmens,et al.  Neuregulin-1 and its potential role in the control of cardiac function. , 2008, Heart failure monitor.

[126]  J. Iredale,et al.  Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. , 2008, The American journal of pathology.

[127]  Hugo A. Katus,et al.  Gene Expression Pattern in Biomechanically Stretched Cardiomyocytes: Evidence for a Stretch-Specific Gene Program , 2008, Hypertension.

[128]  A. Moss,et al.  The Long-QT Syndrome , 1992 .

[129]  J. Struck,et al.  Plasma N-terminal B type natriuretic peptide as an Indicator of Long-term Survival After Acute Myocardial Infarction : Comparison With Plasma Mid-regional Pro-atrial Natriuretic Peptide-Leicester Acute Myocardial Infarction Peptide ( LAMP ) Study , 2008 .

[130]  H. Ostrer,et al.  A KCNE2 mutation in a patient with cardiac arrhythmia induced by auditory stimuli and serum electrolyte imbalance. , 2008, Cardiovascular research.

[131]  Michael J. Ackerman,et al.  Mutation of an A-kinase-anchoring protein causes long-QT syndrome , 2007, Proceedings of the National Academy of Sciences.

[132]  Martin Borggrefe,et al.  In vivo Effects of Mutant HERG K+ Channel Inhibition by Disopyramide in Patients with a Short QT‐1 Syndrome: A Pilot Study , 2007, Journal of cardiovascular electrophysiology.

[133]  Charles Antzelevitch,et al.  Role of spatial dispersion of repolarization in inherited and acquired sudden cardiac death syndromes. , 2007, American journal of physiology. Heart and circulatory physiology.

[134]  P. Ponikowski,et al.  Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. , 2007, Journal of the American College of Cardiology.

[135]  J. Cohn,et al.  Prognostic Value of Very Low Plasma Concentrations of Troponin T in Patients With Stable Chronic Heart Failure , 2007, Circulation.

[136]  Yan-hong Fan,et al.  Arginine vasopressin increases iNOS-NO system activity in cardiac fibroblasts through NF-kappaB activation and its relation with myocardial fibrosis. , 2007, Life sciences.

[137]  G. Breithardt,et al.  Reduction of Dispersion of Repolarization and Prolongation of Postrepolarization Refractoriness Explain the Antiarrhythmic Effects of Quinidine in a Model of Short QT Syndrome , 2007, Journal of cardiovascular electrophysiology.

[138]  Richard T. Lee,et al.  IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. , 2007, The Journal of clinical investigation.

[139]  D. Tester,et al.  Diagnostic Miscues in Congenital Long-QT Syndrome , 2007, Circulation.

[140]  Bba,et al.  Clinical Aspects of Type-1 Long-QT Syndrome by Location, Coding Type, and Biophysical Function of Mutations Involving the KCNQ1 Gene , 2007, Circulation.

[141]  E. Jones,et al.  Heteromeric Assembly of Human Ether-à-go-go-related Gene (hERG) 1a/1b Channels Occurs Cotranslationally via N-terminal Interactions* , 2007, Journal of Biological Chemistry.

[142]  K. Swedberg,et al.  Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. , 2007, JAMA.

[143]  K. Swedberg,et al.  Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. , 2007, JAMA.

[144]  Andrew J. Sauer,et al.  Long QT syndrome in adults. , 2007, Journal of the American College of Cardiology.

[145]  Lauri Toivonen,et al.  The Jervell and Lange-Nielsen Syndrome: Natural History, Molecular Basis, and Clinical Outcome , 2006, Archives des maladies du coeur et des vaisseaux.

[146]  H. Lehr,et al.  Interferon-gamma induces chronic active myocarditis and cardiomyopathy in transgenic mice. , 2007, The American journal of pathology.

[147]  Stefan Britsch,et al.  The neuregulin-I/ErbB signaling system in development and disease. , 2007, Advances in anatomy, embryology, and cell biology.

[148]  J. Struck,et al.  Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure , 2006, European journal of clinical investigation.

[149]  R. Graham,et al.  Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[150]  Michel Haissaguerre,et al.  Short QT syndrome: clinical findings and diagnostic-therapeutic implications. , 2006, European heart journal.

[151]  K. Mori,et al.  Neutrophil gelatinase-associated lipocalin-mediated iron traffic in kidney epithelia , 2006, Current opinion in nephrology and hypertension.

[152]  J. Struck,et al.  Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma. , 2006, Clinical chemistry.

[153]  J. Iredale,et al.  Galectin-3 regulates myofibroblast activation and hepatic fibrosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[154]  D. Mozaffarian,et al.  The Seattle Heart Failure Model: Prediction of Survival in Heart Failure , 2006, Circulation.

[155]  C. January,et al.  Most LQT2 Mutations Reduce Kv11.1 (hERG) Current by a Class 2 (Trafficking-Deficient) Mechanism , 2006, Circulation.

[156]  M. Kawakami,et al.  Possible vascular role of increased plasma arginine vasopressin in congestive heart failure. , 2006, International journal of cardiology.

[157]  M. Ackerman,et al.  Epinephrine QT Stress Testing in the Evaluation of Congenital Long-QT Syndrome: Diagnostic Accuracy of the Paradoxical QT Response , 2005, Circulation.

[158]  D. Mozaffarian,et al.  Prediction of Survival in Heart Failure , 2006 .

[159]  K. Gebo.  Implications for Patient Management , 2006 .

[160]  C. January,et al.  HERG trafficking and pharmacological rescue of LQTS-2 mutant channels. , 2006, Handbook of experimental pharmacology.

[161]  H. Drexler,et al.  The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. , 2006, Circulation research.

[162]  J. Struck,et al.  Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients , 2005, Peptides.

[163]  Frank Sachse,et al.  De novo KCNQ1 mutation responsible for atrial fibrillation and short QT syndrome in utero. , 2005, Cardiovascular research.

[164]  M. Gheorghiade,et al.  Vasopressin antagonism in heart failure. , 2005, Journal of the American College of Cardiology.

[165]  I. Kubota,et al.  Cystatin C, a novel measure of renal function, is an independent predictor of cardiac events in patients with heart failure. , 2005, Journal of cardiac failure.

[166]  J. Struck,et al.  Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. , 2005, Clinical chemistry.

[167]  J. Nerbonne,et al.  Molecular physiology of cardiac repolarization. , 2005, Physiological reviews.

[168]  Dan M Roden,et al.  KCNH2-K897T Is a Genetic Modifier of Latent Congenital Long-QT Syndrome , 2005, Circulation.

[169]  M. Artman,et al.  Expression of ATP-Sensitive K+ Channel Subunits during Perinatal Maturation in the Mouse Heart , 2005, Pediatric Research.

[170]  P. C. Viswanathan,et al.  Genetics of acquired long QT syndrome. , 2005, The Journal of clinical investigation.

[171]  P. Schwartz,et al.  Electrocardiographic Features in Andersen-Tawil Syndrome Patients With KCNJ2 Mutations: Characteristic T-U–Wave Patterns Predict the KCNJ2 Genotype , 2005, Circulation.

[172]  K. Chatterjee.  Neurohormonal activation in congestive heart failure and the role of vasopressin. , 2005, The American journal of cardiology.

[173]  D. Tester,et al.  Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. , 2005, Heart rhythm.

[174]  Kyu-Ho Park,et al.  Impaired KCNQ1–KCNE1 and Phosphatidylinositol-4,5-Bisphosphate Interaction Underlies the Long QT Syndrome , 2005, Circulation research.

[175]  S. Priori,et al.  A Novel Form of Short QT Syndrome (SQT3) Is Caused by a Mutation in the KCNJ2 Gene , 2005, Circulation research.

[176]  F. Gaita,et al.  Short QT syndrome: successful prevention of sudden cardiac death in an adolescent by implantable cardioverter-defibrillator treatment for primary prophylaxis. , 2005, Heart rhythm.

[177]  J. Brugada,et al.  Brugada syndrome: report of the second consensus conference. , 2005, Heart rhythm.

[178]  T. McDonagh,et al.  N‐terminal brain natriuretic peptide is a more powerful predictor of mortality than endothelin‐1, adrenomedullin and tumour necrosis factor‐α in patients referred for consideration of cardiac transplantation , 2005, European journal of heart failure.

[179]  Wataru Shimizu,et al.  Brugada syndrome: report of the second consensus conference. , 2005, Heart rhythm.

[180]  S. Rohrbach,et al.  Neuregulin receptors erbB2 and erbB4 in failing human myocardium , 2005, Basic Research in Cardiology.

[181]  W. Shen,et al.  Epinephrine-induced T-wave notching in congenital long QT syndrome. , 2005, Heart rhythm.

[182]  I. Gussak,et al.  Short QT syndrome: mechanisms, diagnosis and treatment , 2005, Nature Clinical Practice Cardiovascular Medicine.

[183]  B. Psaty,et al.  Cystatin-C and mortality in elderly persons with heart failure. , 2005, Journal of the American College of Cardiology.

[184]  R. Brugada,et al.  Further Insights into the Effect of Quinidine in Short QT Syndrome Caused by a Mutation in HERG , 2005, Journal of cardiovascular electrophysiology.

[185]  R. Kass,et al.  Inherited and acquired vulnerability to ventricular arrhythmias: cardiac Na+ and K+ channels. , 2005, Physiological reviews.

[186]  J. Ketelslegers,et al.  Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study. , 2004, Journal of cardiac failure.

[187]  M. Mitsnefes,et al.  J Am Soc Nephrol 15: 3073–3082, 2004 Amelioration of Ischemic Acute Renal Injury by Neutrophil , 2004 .

[188]  Yigal M. Pinto,et al.  Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction , 2004, Circulation.

[189]  E. Jones,et al.  Cardiac IKr Channels Minimally Comprise hERG 1a and 1b Subunits* , 2004, Journal of Biological Chemistry.

[190]  S. Priori,et al.  Association of Long QT Syndrome Loci and Cardiac Events Among Patients Treated With β-Blockers , 2004 .

[191]  B. Balkau,et al.  New KCNQ1 mutations leading to haploinsufficiency in a general population; Defective trafficking of a KvLQT1 mutant. , 2004, Cardiovascular research.

[192]  J. Buxbaum,et al.  Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia , 2004, Nature Neuroscience.

[193]  A. V. van Ginneken,et al.  Mutation in the KCNQ1 Gene Leading to the Short QT-Interval Syndrome , 2004, Circulation.

[194]  Richard T. Lee,et al.  Serum Levels of the Interleukin-1 Receptor Family Member ST2 Predict Mortality and Clinical Outcome in Acute Myocardial Infarction , 2004, Circulation.

[195]  D. Tester,et al.  Identification of a common genetic substrate underlying postpartum cardiac events in congenital long QT syndrome. , 2004, Heart rhythm.

[196]  S. Priori,et al.  Left Cardiac Sympathetic Denervation in the Management of High-Risk Patients Affected by the Long-QT Syndrome , 2004, Circulation.

[197]  M. Jiang,et al.  KCNE2 Protein Is Expressed in Ventricles of Different Species, and Changes in Its Expression Contribute to Electrical Remodeling in Diseased Hearts , 2004, Circulation.

[198]  J. Tamargo,et al.  Pharmacology of Cardiac Potassium Channels , 2003 .

[199]  J. Brugada,et al.  Sudden Death Associated With Short-QT Syndrome Linked to Mutations in HERG , 2003, Circulation.

[200]  S. Knight.  Long and short , 2004 .

[201]  J. Mason,et al.  A new oral therapy for long QT syndrome: long-term oral potassium improves repolarization in patients with HERG mutations. , 2003, Journal of the American College of Cardiology.

[202]  G. Fonarow,et al.  Cardiac Troponin I Is Associated With Impaired Hemodynamics, Progressive Left Ventricular Dysfunction, and Increased Mortality Rates in Advanced Heart Failure , 2003, Circulation.

[203]  S. Nattel,et al.  Canine Ventricular KCNE2 Expression Resides Predominantly in Purkinje Fibers , 2003, Circulation research.

[204]  J. Vandenberg,et al.  Mutant MiRP1 subunits modulate HERG K+ channel gating: a mechanism for pro‐arrhythmia in long QT syndrome type 6 , 2003, The Journal of physiology.

[205]  Douglas L Packer,et al.  Familial atrial fibrillation is a genetically heterogeneous disorder. , 2003, Journal of the American College of Cardiology.

[206]  Carlo Napolitano,et al.  Risk stratification in the long-QT syndrome. , 2003, The New England journal of medicine.

[207]  S. Viskin.  Implantable Cardioverter Defibrillator in High‐Risk Long QT Syndrome Patients , 2003, Journal of cardiovascular electrophysiology.

[208]  S. Priori,et al.  Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome. , 2003, Journal of the American College of Cardiology.

[209]  Richard T. Lee,et al.  Identification of Serum Soluble ST2 Receptor as a Novel Heart Failure Biomarker , 2003, Circulation.

[210]  Jennifer L. Robinson,et al.  Long QT Syndrome. , 2003, JAMA.

[211]  A. Paulussen,et al.  A Novel Mutation (T65P) in the PAS Domain of the Human Potassium Channel HERG Results in the Long QT Syndrome by Trafficking Deficiency* , 2002, The Journal of Biological Chemistry.

[212]  Richard T. Lee,et al.  Expression and Regulation of ST2, an Interleukin-1 Receptor Family Member, in Cardiomyocytes and Myocardial Infarction , 2002, Circulation.

[213]  A. Coats,et al.  Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? , 2002, International journal of cardiology.

[214]  K. Baughman.  B-type natriuretic peptide -- a window to the heart. , 2002, The New England journal of medicine.

[215]  G. Breithardt,et al.  Identification and functional characterization of a novel KCNE2 (MiRP1) mutation that alters HERG channel kinetics , 2002, Journal of Molecular Medicine.

[216]  C. January,et al.  Pharmacological Rescue of Human K+ Channel Long-QT2 Mutations: Human Ether-a-Go-Go-Related Gene Rescue Without Block , 2002, Circulation.

[217]  Stanley Nattel,et al.  Differential Distribution of Cardiac Ion Channel Expression as a Basis for Regional Specialization in Electrical Function , 2002, Circulation research.

[218]  W. Shen,et al.  Epinephrine-induced QT interval prolongation: a gene-specific paradoxical response in congenital long QT syndrome. , 2002, Mayo Clinic proceedings.

[219]  J. Burnett,et al.  Adrenomedullin: an autocrine/paracrine factor for cardiorenal protection. , 2002, Circulation research.

[220]  Stanley Nattel,et al.  A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link? , 2002, The Journal of physiology.

[221]  Derick R. Peterson,et al.  Increased Risk of Arrhythmic Events in Long-QT Syndrome With Mutations in the Pore Region of the Human Ether-a-go-go–Related Gene Potassium Channel , 2002, Circulation.

[222]  Junko Kurokawa,et al.  Requirement of a Macromolecular Signaling Complex for β Adrenergic Receptor Modulation of the KCNQ1-KCNE1 Potassium Channel , 2002, Science.

[223]  B. Sunsaneewitayakul,et al.  New electrocardiographic leads and the procainamide test for the detection of the Brugada sign in sudden unexplained death syndrome survivors and their relatives , 2001 .

[224]  M. Redfield,et al.  Regulation of cardiac adrenomedullin in heart failure , 2001, Peptides.

[225]  S. Subramony,et al.  Mutations in Kir2.1 Cause the Developmental and Episodic Electrical Phenotypes of Andersen's Syndrome , 2001, Cell.

[226]  G. Breithardt,et al.  Life-threatening Arrhythmias Genotype-phenotype Correlation in the Long-qt Syndrome : Gene-specific Triggers for Genotype-phenotype Correlation in the Long-qt Syndrome Gene-specific Triggers for Life-threatening Arrhythmias , 2022 .

[227]  J. Ghali,et al.  Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. , 2001, Circulation.

[228]  J. Brugada,et al.  Idiopathic Short QT Interval:A New Clinical Syndrome? , 2001, Cardiology.

[229]  A J Moss,et al.  Spectrum of Mutations in Long-QT Syndrome Genes: KVLQT1, HERG, SCN5A, KCNE1, and KCNE2 , 2000, Circulation.

[230]  H. Nishimatsu,et al.  Adrenomedullin and nitric oxide inhibit human endothelial cell apoptosis via a cyclic GMP-independent mechanism. , 2000, Hypertension.

[231]  M. Komajda,et al.  Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure. , 2000, European heart journal.

[232]  W. Shimizu,et al.  Body Surface Distribution and Response to Drugs of ST Segment Elevation in Brugada Syndrome: Clinical Implication of Eighty‐Seven–Lead Body Surface Potential Mapping and Its Application to Twelve‐Lead Electrocardiograms , 2000, Journal of cardiovascular electrophysiology.

[233]  Y Shinagawa,et al.  The sustained inward current and inward rectifier K+ current in pacemaker cells dissociated from rat sinoatrial node , 2000, The Journal of physiology.

[234]  S. Priori,et al.  Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. , 2000, Circulation.

[235]  B Attali,et al.  A recessive C‐terminal Jervell and Lange‐Nielsen mutation of the KCNQ1 channel impairs subunit assembly , 2000, The EMBO journal.

[236]  Lucila Ohno-Machado,et al.  Risk stratification in heart failure using artificial neural networks , 2000, AMIA.

[237]  M. Kinoshita,et al.  Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. , 1999, European heart journal.

[238]  M. Itakura,et al.  Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. , 1999, European journal of biochemistry.

[239]  D. Snyders,et al.  Structure and function of cardiac potassium channels. , 1999, Cardiovascular research.

[240]  M. Keating,et al.  MiRP1 Forms IKr Potassium Channels with HERG and Is Associated with Cardiac Arrhythmia , 1999, Cell.

[241]  B. Rudy,et al.  Molecular Diversity of K+ Channels , 1999, Annals of the New York Academy of Sciences.

[242]  S. Priori,et al.  Low penetrance in the long-QT syndrome: clinical impact. , 1999, Circulation.

[243]  R. Hauer,et al.  Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KVLQT1-related patients (LQTS1). , 1999, Journal of the American College of Cardiology.

[244]  R. Numann,et al.  Independent and exclusive modulation of cardiac delayed rectifying K+ current by protein kinase C and protein kinase A. , 1998, Circulation research.

[245]  G. Maurer,et al.  Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. , 1998, Journal of the American College of Cardiology.

[246]  C. January,et al.  HERG Channel Dysfunction in Human Long QT Syndrome , 1998, The Journal of Biological Chemistry.

[247]  B. Keevil,et al.  Biological variation of cystatin C: implications for the assessment of glomerular filtration rate. , 1998, Clinical chemistry.

[248]  A. Moss,et al.  Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. LQTS Investigators. , 1998, Circulation.

[249]  Francisco Bezanilla,et al.  [19] Gating currents , 1998 .

[250]  K. Nademanee,et al.  Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. , 1997, Circulation.

[251]  W. D. Fairlie,et al.  MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[252]  J. Cowland,et al.  Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. , 1997, Genomics.

[253]  Yosef Yarden,et al.  Neuregulins and Their Receptors: A Versatile Signaling Module in Organogenesis and Oncogenesis , 1997, Neuron.

[254]  D. Clapham,et al.  Ion channels--basic science and clinical disease. , 1997, The New England journal of medicine.

[255]  R. Schrier,et al.  Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. , 1997, The Journal of clinical investigation.

[256]  M. Komajda,et al.  Prognostic value of plasma endothelin-1 in patients with chronic heart failure. , 1997, European heart journal.

[257]  M. Sanguinetti,et al.  Coassembly of KVLQT1 and minK (IsK) proteins to form cardiac IKS potassium channel , 1996, Nature.

[258]  Jacques Barhanin,et al.  KvLQT1 and IsK (minK) proteins associate to form the IKS cardiac potassium current , 1996, Nature.

[259]  G. Landes,et al.  Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias , 1996, Nature Genetics.

[260]  S. Priori,et al.  Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. , 1995, Circulation.

[261]  T. Ishimitsu,et al.  Increased plasma levels of adrenomedullin in patients with heart failure. , 1995, Journal of the American College of Cardiology.

[262]  A. Moss,et al.  ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. , 1995, Circulation.

[263]  D. Fukai,et al.  Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure. , 1995, The American journal of cardiology.

[264]  J. Burnett,et al.  Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. , 1995, Circulation.

[265]  M. Mehta,et al.  Early Repolarization on Scalar Electrocardiogram , 1995, The American journal of the medical sciences.

[266]  R. MacKinnon,et al.  Pore loops: An emerging theme in ion channel structure , 1995, Neuron.

[267]  E. Green,et al.  A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome , 1995, Cell.

[268]  U. Ravens,et al.  Transient outward current in human ventricular myocytes of subepicardial and subendocardial origin. , 1994, Circulation research.

[269]  Peter J. Schwartz,et al.  Diagnostic Criteria for the Long QT Syndrome An Update , 1993, Circulation.

[270]  J. Brugada,et al.  Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. , 1992, Journal of the American College of Cardiology.

[271]  G. Vincent,et al.  Effects of exercise on heart rate, QT, QTc and QT/QS2 in the Romano-Ward inherited long QT syndrome. , 1991, The American journal of cardiology.

[272]  J. Remes,et al.  Validity of clinical diagnosis of heart failure in primary health care. , 1991, European heart journal.

[273]  J. Jalife,et al.  Electrophysiology of single heart cells from the rabbit tricuspid valve. , 1990, The Journal of physiology.

[274]  L. Stevenson,et al.  The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. , 1989, JAMA.

[275]  W. Giles,et al.  Comparison of potassium currents in rabbit atrial and ventricular cells. , 1988, The Journal of physiology.

[276]  C. Antzelevitch,et al.  Transient Outward Current Prominent in Canine Ventricular Epicardium but Not Endocardium , 1988, Circulation research.

[277]  J. Cohn,et al.  Hemodynamic effects of infused arginine vasopressin in congestive heart failure. , 1986, Journal of the American College of Cardiology.

[278]  G. A. Durham,et al.  A y‐year follow‐up study of ninety patients with psoriasis , 1974, The British journal of dermatology.

[279]  R. H. Wasserburger,et al.  The normal RS-T segment elevation variant. , 1961, The American journal of cardiology.

[280]  H C Bazett,et al.  The time relations of the blood‐pressure changes after excision of the adrenal glands, with some observations on blood volume changes , 1920, The Journal of physiology.

[281]  P. Freedson,et al.  Scientific Statement From the American Heart Association Guide to the Assessment of Physical Activity: Clinical and Research Applications: A , 2015 .